financetom
Business
financetom
/
Business
/
Williams-Sonoma Beats Q4 Estimates But Stock Tumbles On Soft 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Williams-Sonoma Beats Q4 Estimates But Stock Tumbles On Soft 2025 Outlook
Mar 19, 2025 8:19 AM

Williams-Sonoma, Inc. ( WSM ) stock plummeted after the company reported fourth-quarter 2024 results.

On Wednesday, the company reported that fourth-quarter revenue grew 8% year over year to $2.46 billion, beating the consensus of $2.35 billion. Comparable brand revenue was up 3.1%.

Adjusted earnings per share were $3.28, up from $2.72 the previous year, and above the analyst consensus of $2.93.

The gross margin expanded by 133 basis points to 47.3% from last year, driven by occupancy leverage (+80bps), higher merchandise margins (+40bps), and supply chain efficiencies (+10bps).

Related: Williams-Sonoma Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

Operating income reached $530.14 million (+15.7% YoY), with a record operating margin of 21.5%, up 140 bps year over year. Merchandise inventories grew 6.9% YoY to $1.33 billion.

The company maintained a liquidity position of $1.2 billion in cash and operating cash flow of $1.4 billion. It returned $1.1 billion to stockholders through $807 million in stock repurchases and $280 million in dividends.

“This success was fueled by the strength of our operating model, our standout seasonal offerings, our impactful collaborations, and a strong improvement in both retail and online furniture sales. On the full year, our comp ran down 1.6%. We delivered a record annual operating margin of 17.9% with full-year earnings per share of $8.50,” stated Laura Alber, President and Chief Executive Officer.

Dividend: Williams-Sonoma ( WSM ) announced a 16% increase in its quarterly dividend to $0.66 per share, payable May 24, 2025, to shareholders of record as of April 17.

2025 Outlook: Williams-Sonoma ( WSM ) net revenue is expected to range from -1.5% to +1.5%, comps from flat to +3.0%, and operating margin between 17.4% and 17.8%, including a 20bps impact from the prior year’s extra week.

Long-Term Guidance: The company continues to project mid-to-high single-digit annual revenue growth and operating margins in the mid-to-high teens.

Fiscal 2025 is a 52-week year vs. 53 weeks in fiscal 2024; comps will be reported on a 52-week basis for both years.

Price Action: Williams-Sonoma ( WSM ) shares are trading lower by 11.1% at $153.14 at last check Wednesday.

Also Read:

Nasdaq Gains Over 1%; Williams-Sonoma Shares Plunge After Q4 Results

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Berkshire's PacifiCorp ordered to pay $29.2 million to homeowners, summer camp for 2020 Oregon wildfire damage
Berkshire's PacifiCorp ordered to pay $29.2 million to homeowners, summer camp for 2020 Oregon wildfire damage
Mar 5, 2024
(Reuters) - An Oregon state jury on Tuesday ordered Berkshire Hathaway's ( BRK/A ) PacifiCorp ( PPWLM ) to pay at least $29.2 million to nine homeowners and a summer camp whose properties were damaged by 2020 wildfires they claim were sparked when the Oregon utility failed to shut off its power lines during high winds. The verdict came in...
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Mar 5, 2024
Immutep Limited ( IMMP ) announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase 2/3 trial. Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events. ...
Campbell Soup Positioned For Largely In-Line Second Quarter, RBC Says
Campbell Soup Positioned For Largely In-Line Second Quarter, RBC Says
Mar 5, 2024
04:02 PM EST, 03/05/2024 (MT Newswires) -- Campbell Soup ( CPB ) is positioned for a largely in-line fiscal second quarter with possible top-line upside amid strong January soup trends, though the consumer packaged food industry remains challenged, RBC Capital Markets said Tuesday. Campbell's salty snacks category continues to slow and its soup business faces pressure from a trade-down to...
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Mar 5, 2024
04:04 PM EST, 03/05/2024 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata. The Phase 2b study will evaluate rezpegaldesleukin's efficacy and safety in 84 participants with severe alopecia areata over a 36-week period using a randomized, double-blind, placebo-controlled dosage, Nektar...
Copyright 2023-2026 - www.financetom.com All Rights Reserved